Keito Hoshitsuki

Keito Hoshitsuki

Auto-generated profile, based on publicly available information

Keito Hoshitsuki

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TMTakaya Moriyama
Takaya Moriyama
RNRina Nishii
Rina Nishii
VPVirginia Perez-Andreu
Virginia Perez-Andreu
WYWenjian Yang
Wenjian Yang
FKFederico Antillon Klussmann
Federico Antillon Klussmann
JYJun Yang
Jun Yang

24 February 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CSChase C. Suiter
Chase C. Suiter
TMTakaya Moriyama
Takaya Moriyama
KMKenneth Matreyek
Kenneth Matreyek
WYWentao Yang
Wentao Yang
ESEmma Rose Scaletti
Emma Rose Scaletti
JYJun Yang
Jun Yang
Significance: Pharmacogenetics is a prototype of genomics-guided precision medicine. While there is a rapid expansion of novel pharmacogenetic variants discovered by genome sequencing, the lack of variant interpretation in a scalable fashion is a formidable barrier in this field.NUDT15polymorphism is a major genetic cause for hematopoietic toxicity during thiopurine therapy. Motivated by the need to understandNUDT15variant effects for clinical actions, we developed a massively parallel assay to preemptively characterize 91.8% of all possible missense variants inNUDT15. Our function-based variant classification accurately predicted thiopurine toxicity risk alleles in patients. These results vastly improved the ability to implement genotype-guided thiopurine therapy and illustrated the value and potential of a high-throughput variant effect screen in general.

21 January 2021 in Blood
Verified
Journal Article
Open access
PDF file
RNRina Nishii
Rina Nishii
RBRebekah Baskin-Doerfler
Rebekah Baskin-Doerfler
WYWentao Yang
Wentao Yang
NONinad Oak
Ninad Oak
XZXujie Zhao
Xujie Zhao
JYJun Yang
Jun Yang
There is growing evidence supporting an inherited basis for susceptibility to acute lymphoblastic leukemia (ALL) in children. In particular, we and others reported recurrent germline ETV6 variants linked to ALL risk, which collectively represent a novel leukemia predisposition syndrome. To understand the influence of ETV6 variation on ALL pathogenesis, we comprehensively characterized a cohort of 32 childhood leukemia cases arising from this rare syndrome. Of 34 nonsynonymous germline ETV6 variants in ALL, we identified 22 variants with impaired transcription repressor activity, loss of DNA binding, and altered nuclear localization. Missense variants retained dimerization with wild-type ETV6 with potentially dominant-negative effects. Whole-transcriptome and whole-genome sequencing of this cohort of leukemia cases revealed a profound influence of germline ETV6 variants on leukemia transcriptional landscape, with distinct ALL subsets invoking unique patterns of somatic cooperating mutations. 70% of ALL cases with damaging germline ETV6 variants exhibited hyperdiploid karyotype with characteristic recurrent mutations in NRAS, KRAS, and PTPN11. In contrast, the remaining 30% cases had a diploid leukemia genome and an exceedingly high frequency of somatic copy-number loss of PAX5 and ETV6, with a gene expression pattern that strikingly mirrored that of ALL with somatic ETV6-RUNX1 fusion. Two ETV6 germline variants gave rise to both acute myeloid leukemia and ALL, with lineage-specific genetic lesions in the leukemia genomes. ETV6 variants compromise its tumor suppressor activity in vitro with specific molecular targets identified by assay for transposase-accessible chromatin sequencing profiling. ETV6-mediated ALL predisposition exemplifies the intricate interactions between inherited and acquired genomic variations in leukemia pathogenesis.

1 September 2018 in Journal of Neurotrauma
Verified
Journal Article
Closed access
RJRuchira Jha
Ruchira Jha
BMBradley J. Molyneaux
Bradley J. Molyneaux
TJTravis C. Jackson
Travis C. Jackson
JWJessica S. Wallisch
Jessica S. Wallisch
SPSeo-Young Park
Seo-Young Park
PKPatrick M. Kochanek
Patrick M. Kochanek
Cerebral edema is critical to morbidity/mortality in traumatic brain injury (TBI) and is worsened by hypotension. Glibenclamide may reduce cerebral edema by inhibiting sulfonylurea receptor-1 (Sur1); its effect on diffuse cerebral edema exacerbated by hypotension/resuscitation is unknown. We aimed to determine if glibenclamide improves pericontusional and/or diffuse edema in controlled cortical impact (CCI) (5m/sec, 1 mm depth) plus hemorrhagic shock (HS) (35 min), and compare its effects in CCI alone. C57BL/6 mice were divided into five groups (n = 10/group): naïve, CCI+vehicle, CCI+glibenclamide, CCI+HS+vehicle, and CCI+HS+glibenclamide. Intravenous glibenclamide (10 min post-injury) was followed by a subcutaneous infusion for 24 h. Brain edema in injured and contralateral hemispheres was subsequently quantified (wet-dry weight). This protocol brain water (BW) = 80.4% vehicle vs. 78.3% naïve, p < 0.01) but was not reduced by glibenclamide (I%BW = 80.4%). Ipsilateral edema also developed in CCI alone (I%BW = 80.2% vehicle vs. 78.3% naïve, p < 0.01); again unaffected by glibenclamide (I%BW = 80.5%). Contralateral (C) %BW in CCI+HS was increased in vehicle (78.6%) versus naive (78.3%, p = 0.02) but unchanged in CCI (78.3%). At 24 h, glibenclamide treatment in CCI+HS eliminated contralateral cerebral edema (C%BW = 78.3%) with no difference versus naïve. By 72 h, contralateral cerebral edema had resolved (C%BW = 78.5 ± 0.09% vehicle vs. 78.3 ± 0.05% naïve). Glibenclamide decreased 24 h contralateral cerebral edema in CCI+HS. This beneficial effect merits additional exploration in the important setting of TBI with polytrauma, shock, and resuscitation. Contralateral edema did not develop in CCI alone. Surprisingly, 24 h of glibenclamide treatment failed to decrease ipsilateral edema in either model. Interspecies dosing differences versus prior studies may play an important role in these findings. Mechanisms underlying brain edema may differ regionally, with pericontusional/osmolar swelling refractory to glibenclamide but diffuse edema (via Sur1) from combined injury and/or resuscitation responsive to this therapy. TBI phenotype may mandate precision medicine approaches to treat brain edema.

26 July 2017 in Journal of Pediatric Intensive Care
Verified
Journal Article
Closed access
PDF file
KCKelli Crowley
Kelli Crowley
CVCarol Vetterly
Carol Vetterly
KHKeito Hoshitsuki
Keito Hoshitsuki
AKAlaina Koval
Alaina Koval
JCJoseph Carcillo
Joseph Carcillo
DFDana Fuhrman
Dana Fuhrman
In this prospective observational study, we explored the association of daily fluid intake from medication use with fluid overload in 75 children beginning 24 hours after intubation. The mean percent daily fluid intake from medications was 29% in the overall cohort. Excess intake and inadequate output contributed significantly to fluid overload. In the 28 patients who became ≥10% fluid overloaded, the mean percent daily fluid intake from medications was 34%, but just 23% in the patients who did not. Awareness of volume contribution and maximized concentration of parenteral medications when able may lessen the burden of fluid overload.

29 June 2021 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
KHKeito Hoshitsuki
Keito Hoshitsuki
CFChristian A. Fernandez
Christian A. Fernandez
JYJun Yang
Jun Yang
Pharmacogenomics research ranges from the discovery of genetic factors to explain interpatient variability in drug exposure and response to clinical implementation of this knowledge to improve pharmacotherapy. Medications with actionable pharmacogenomic associations are frequently used in children, and therefore pharmacogenomics‐guided precision medicine is readily applicable to the pediatric population. Although heritable genetics are considered immutable, the impact of genetic variation in pharmacogenes is modified by other factors such as age‐dependent changes in gene expression. Early evidence has emerged indicating that the interaction between ontogeny and pharmacogenomics determines whether or how genetics‐based dosing algorithms should be adjusted in children versus adults. However, there is still a paucity of data describing pharmacogenomic associations in patient populations across the life span. Future research is much needed to evaluate the impact of pharmacogenomics on drug dosing specific to the pediatric population, along with consideration of other developmental and physiological factors uniquely related to drug disposition in this population.